Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $22.8182.

Several equities research analysts have issued reports on ATEC shares. Barclays increased their price target on Alphatec from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Stifel Nicolaus lowered their price target on Alphatec from $24.00 to $20.00 and set a “buy” rating for the company in a report on Monday, March 9th. Piper Sandler restated an “overweight” rating on shares of Alphatec in a report on Wednesday, February 25th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Alphatec in a report on Monday, January 12th. Finally, Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 31st.

Insider Transactions at Alphatec

In related news, COO Scott Lish sold 260,535 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the completion of the transaction, the chief operating officer directly owned 815,704 shares in the company, valued at approximately $10,033,159.20. This trade represents a 24.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 163,452 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $12.52, for a total value of $2,046,419.04. Following the transaction, the executive vice president owned 504,932 shares of the company’s stock, valued at approximately $6,321,748.64. The trade was a 24.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 726,972 shares of company stock valued at $9,184,386 in the last ninety days. Corporate insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Alphatec by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock valued at $99,091,000 after purchasing an additional 158,295 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Alphatec by 7,083.2% during the third quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company’s stock valued at $10,911,000 after purchasing an additional 739,982 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in Alphatec by 608.4% during the third quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock valued at $13,093,000 after purchasing an additional 773,367 shares during the last quarter. Lisanti Capital Growth LLC acquired a new position in Alphatec during the third quarter valued at approximately $3,305,000. Finally, SG Americas Securities LLC acquired a new position in Alphatec during the third quarter valued at approximately $1,115,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Stock Up 6.8%

Shares of Alphatec stock opened at $10.90 on Friday. Alphatec has a 1 year low of $10.05 and a 1 year high of $23.29. The business has a 50-day moving average of $12.08 and a two-hundred day moving average of $16.05. The company has a market capitalization of $1.65 billion, a P/E ratio of -11.47 and a beta of 1.12. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. During the same quarter last year, the company earned ($0.23) earnings per share. The firm’s revenue was up 20.4% compared to the same quarter last year. As a group, equities analysts predict that Alphatec will post -0.28 EPS for the current year.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.